Last reviewed · How we verify
Dual Anti Platelet Therapy
Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.
Dual antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of myocardial infarction.
At a glance
| Generic name | Dual Anti Platelet Therapy |
|---|---|
| Sponsor | Biosensors Europe SA |
| Drug class | Antiplatelet agent combination |
| Target | Thromboxane A2 pathway and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This approach typically combines an inhibitor of thromboxane A2 synthesis (such as aspirin) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide complementary antiplatelet effects. By blocking platelet activation through multiple pathways, dual antiplatelet therapy reduces the risk of stent thrombosis and recurrent ischemic events in cardiovascular disease.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention with stent placement
- Secondary prevention of myocardial infarction
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Dyspepsia
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- Duration of Dual Anti-Platelet Therapy (DUAL-ACS) (PHASE4)
- Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE (PHASE3)
- Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD) (NA)
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Dissection of the Superior Mesenteric Artery
- Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dual Anti Platelet Therapy CI brief — competitive landscape report
- Dual Anti Platelet Therapy updates RSS · CI watch RSS
- Biosensors Europe SA portfolio CI